Mako Pushes Off Expectations For Bicompartmental Knee Procedure
This article was originally published in The Gray Sheet
Mako Surgical has big expectations for its robotic approach to knee resurfacing in patients with moderate osteoarthritis, but the firm does not plan to pursue serious inroads into a large swath of the market for at least another year
You may also be interested in...
561 knee resurfacing procedures were performed using the company's robotic system and implants in the fourth quarter of 2009, up 34% from the third quarter and 181% from Q4 2008, Mako said in its March 8 earnings report for 2009. Also, seven new RIO robotic arm systems were installed during the quarter, bringing the total installed base to 36. Mako reported $8.9 million in revenue for the quarter, up from $1 million in the prior-year period. The company is expecting data to come out later this year on use of its products for bicompartmental knee resurfacing, which the company sees as a major market opportunity (1"The Gray Sheet" Nov. 9, 2009)
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.